Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Challenges with Novel Clinical Trial Designs: Master Protocols.

Cecchini M, Rubin EH, Blumenthal GM, Ayalew K, Burris HA, Russell-Einhorn M, Dillon H, Lyerly HK, Reaman GH, Boerner S, LoRusso PM.

Clin Cancer Res. 2019 Apr 1;25(7):2049-2057. doi: 10.1158/1078-0432.CCR-18-3544. Epub 2019 Jan 29.

PMID:
30696689
2.

Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.

Schore RJ, Devidas M, Bleyer A, Reaman GH, Winick N, Loh ML, Raetz EA, Carroll WL, Hunger SP, Angiolillo AL.

Leuk Lymphoma. 2019 Jan 10:1-9. doi: 10.1080/10428194.2018.1542146. [Epub ahead of print]

PMID:
30626253
3.

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.

Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, Wood BL, Kelloff GJ, Jessup JM, Radich JP.

JAMA Oncol. 2017 Jul 13;3(7):e170580. doi: 10.1001/jamaoncol.2017.0580. Epub 2017 Jul 13.

4.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

5.

Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents.

Chuk MK, Mulugeta Y, Roth-Cline M, Mehrotra N, Reaman GH.

Clin Cancer Res. 2017 Jan 1;23(1):9-12. doi: 10.1158/1078-0432.CCR-16-1367. Epub 2016 Oct 25.

6.

Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.

Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E, Carrington L, Marti GE.

Cytometry B Clin Cytom. 2016 Jan;90(1):73-80. doi: 10.1002/cyto.b.21268. Epub 2015 Jul 25.

7.

Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports.

Cope JU, Reaman GH, Tonning JM.

Sarcoma. 2015;2015:948159. doi: 10.1155/2015/948159. Epub 2015 May 7. Review.

8.

CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.

Uckun FM, Qazi S, Ma H, Reaman GH, Mitchell LG.

Integr Biol (Camb). 2015 Feb;7(2):237-49. doi: 10.1039/c4ib00221k.

9.

Remaining challenges in childhood cancer and newer targeted therapeutics.

Smith MA, Reaman GH.

Pediatr Clin North Am. 2015 Feb;62(1):301-12. doi: 10.1016/j.pcl.2014.09.018. Epub 2014 Oct 18. Review.

10.

Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).

Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM.

Pediatr Blood Cancer. 2015 Mar;62(3):419-26. doi: 10.1002/pbc.25322. Epub 2014 Nov 14.

11.

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Keilani T, Lane AR, Loh ML, Reaman GH, Adamson PC, Wood B, Wood C, Zheng HW, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

J Clin Oncol. 2014 Dec 1;32(34):3874-82. doi: 10.1200/JCO.2014.55.5763. Epub 2014 Oct 27.

12.

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.

Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M, Reaman GH, Scorsone K, Sung L, Dolan ME, Berg SL.

Cancer Chemother Pharmacol. 2014 Oct;74(4):831-8. doi: 10.1007/s00280-014-2535-4. Epub 2014 Aug 14.

13.

The Children's Oncology Group Childhood Cancer Research Network (CCRN): case catchment in the United States.

Musselman JR, Spector LG, Krailo MD, Reaman GH, Linabery AM, Poynter JN, Stork SK, Adamson PC, Ross JA.

Cancer. 2014 Oct 1;120(19):3007-15. doi: 10.1002/cncr.28813. Epub 2014 May 29.

14.

Declining childhood and adolescent cancer mortality.

Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL.

Cancer. 2014 Aug 15;120(16):2497-506. doi: 10.1002/cncr.28748. Epub 2014 May 22.

15.

DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development.

Shah ED, Fisch BM, Arceci RJ, Buckley JD, Reaman GH, Sorensen PH, Triche TJ, Reynolds CP.

Cancer Chemother Pharmacol. 2014 May;73(5):1089-93. doi: 10.1007/s00280-014-2433-9. Epub 2014 Mar 25.

PMID:
24663501
16.

Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: a prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA).

Al-Mulla NA, Chandra P, Khattab M, Madanat F, Vossough P, Torfa E, Al-Lamki Z, Zain G, Muwakkit S, Mahmoud S, Al-Jassmi A, Tuncer M, Al-Mukharraq H, Barsaoui S, Arceci RJ, Howard SC, Kulozik AE, Ravindranath Y, Reaman GH, Farranoush M, AlNasser AA.

Pediatr Blood Cancer. 2014 Aug;61(8):1403-10. doi: 10.1002/pbc.25031. Epub 2014 Mar 20.

PMID:
24648275
17.

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP.

Blood. 2013 Jul 25;122(4):507-14. doi: 10.1182/blood-2013-01-480822. Epub 2013 Jun 5.

18.

Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries.

Pritchard-Jones K, Pieters R, Reaman GH, Hjorth L, Downie P, Calaminus G, Naafs-Wilstra MC, Steliarova-Foucher E.

Lancet Oncol. 2013 Mar;14(3):e95-e103. doi: 10.1016/S1470-2045(13)70010-X. Epub 2013 Feb 20.

PMID:
23434338
19.

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.

Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, Cao K, Cory L, Moore JS, Bantly AD, Yu QC, Chen IM, Atlas SR, Willman CL, Kundu M, Carroll AJ, Heerema NA, Devidas M, Hilden JM, Dreyer ZE, Hunger SP, Reaman GH, Felix CA.

Blood. 2013 Apr 4;121(14):2689-703. doi: 10.1182/blood-2012-04-425033. Epub 2013 Feb 7.

20.

American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care.

McCabe MS, Bhatia S, Oeffinger KC, Reaman GH, Tyne C, Wollins DS, Hudson MM.

J Clin Oncol. 2013 Feb 10;31(5):631-40. doi: 10.1200/JCO.2012.46.6854. Epub 2013 Jan 7. No abstract available.

21.

Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.

Yang JJ, Cheng C, Devidas M, Cao X, Campana D, Yang W, Fan Y, Neale G, Cox N, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Bowman WP, Camitta B, Reaman GH, Carroll WL, Willman CL, Hunger SP, Evans WE, Pui CH, Loh M, Relling MV.

Blood. 2012 Nov 15;120(20):4197-204. doi: 10.1182/blood-2012-07-440107. Epub 2012 Sep 24.

22.

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.

Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL.

J Clin Oncol. 2012 May 10;30(14):1663-9. doi: 10.1200/JCO.2011.37.8018. Epub 2012 Mar 12.

23.

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.

Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, Borowitz MJ, Camitta BM, Carroll AJ, Devidas M, Pullen DJ, Payne-Turner D, Tasian SK, Reshmi S, Cottrell CE, Reaman GH, Bowman WP, Carroll WL, Loh ML, Winick NJ, Hunger SP, Willman CL.

Blood. 2012 Apr 12;119(15):3512-22. doi: 10.1182/blood-2011-11-394221. Epub 2012 Feb 24.

24.

ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.

Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W, Neale G, Scheet P, Burchard EG, Torgerson DG, Eng C, Dean M, Antillon F, Winick NJ, Martin PL, Willman CL, Camitta BM, Reaman GH, Carroll WL, Loh M, Evans WE, Pui CH, Hunger SP, Relling MV, Yang JJ.

J Clin Oncol. 2012 Mar 1;30(7):751-7. doi: 10.1200/JCO.2011.38.0345. Epub 2012 Jan 30.

25.

Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

Kang H, Wilson CS, Harvey RC, Chen IM, Murphy MH, Atlas SR, Bedrick EJ, Devidas M, Carroll AJ, Robinson BW, Stam RW, Valsecchi MG, Pieters R, Heerema NA, Hilden JM, Felix CA, Reaman GH, Camitta B, Winick N, Carroll WL, Dreyer ZE, Hunger SP, Willman CL.

Blood. 2012 Feb 23;119(8):1872-81. doi: 10.1182/blood-2011-10-382861. Epub 2011 Dec 30.

26.

Successful Integration of Cooperative Groups: The Origin of the Children's Oncology Group.

Reaman GH.

Am Soc Clin Oncol Educ Book. 2012:149-51. doi: 10.14694/EdBook_AM.2012.32.149.

27.

CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.

Ma H, Qazi S, Ozer Z, Gaynon P, Reaman GH, Uckun FM.

Br J Haematol. 2012 Jan;156(1):89-98. doi: 10.1111/j.1365-2141.2011.08901.x. Epub 2011 Oct 21.

PMID:
22017452
28.

What price cure?

Billett AL, Reaman GH.

Pediatr Blood Cancer. 2011 Dec 1;57(6):908-9. No abstract available.

PMID:
22010290
29.

Feasibility of neonatal dried blood spot retrieval amid evolving state policies (2009-2010): a Children's Oncology Group study.

Linabery AM, Slater ME, Spector LG, Olshan AF, Stork SK, Roesler MA, Reaman GH, Ross JA.

Paediatr Perinat Epidemiol. 2011 Nov;25(6):549-58. doi: 10.1111/j.1365-3016.2011.01228.x. Epub 2011 Aug 10.

30.

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.

Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Blood. 2011 Oct 27;118(17):4561-6. doi: 10.1182/blood-2011-04-348888. Epub 2011 Aug 26.

31.

MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children's Oncology Group (COG) study.

Sam TN, Kersey JH, Linabery AM, Johnson KJ, Heerema NA, Hilden JM, Davies SM, Reaman GH, Ross JA.

Pediatr Blood Cancer. 2012 Jun;58(6):836-9. doi: 10.1002/pbc.23274. Epub 2011 Jul 28.

32.

Childhood cancer survivorship educational resources in North American hematology/oncology fellowship training programs: a survey study.

Reaman GH.

Pediatr Blood Cancer. 2011 Dec 15;57(7):1097. doi: 10.1002/pbc.23243. Epub 2011 Jul 9. No abstract available.

PMID:
21744484
33.

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M, Buetow KH, Carroll WL, Chen IM, Devidas M, Gerhard DS, Loh ML, Reaman GH, Relling MV, Camitta BM, Bowman WP, Smith MA, Willman CL, Downing JR, Hunger SP.

Blood. 2011 Sep 15;118(11):3080-7. doi: 10.1182/blood-2011-03-341412. Epub 2011 Jun 16.

34.

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.

Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox NJ, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, Camitta BM, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui CH, Evans WE, Relling MV.

Nat Genet. 2011 Mar;43(3):237-41. doi: 10.1038/ng.763. Epub 2011 Feb 6.

35.

Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group.

Dreyer ZE, Dinndorf PA, Camitta B, Sather H, La MK, Devidas M, Hilden JM, Heerema NA, Sanders JE, McGlennen R, Willman CL, Carroll AJ, Behm F, Smith FO, Woods WG, Godder K, Reaman GH.

J Clin Oncol. 2011 Jan 10;29(2):214-22. doi: 10.1200/JCO.2009.26.8938. Epub 2010 Dec 6.

36.

Health care reform 2010: expected favorable impact on childhood cancer patients and survivors.

Wolfson J, Ruccione K, Reaman GH.

Cancer J. 2010 Nov-Dec;16(6):554-62. doi: 10.1097/PPO.0b013e3181feee83. Review.

PMID:
21131785
37.

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.

Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, Chen IM, Atlas SR, Kang H, Ar K, Wilson CS, Wharton W, Murphy M, Devidas M, Carroll AJ, Borowitz MJ, Bowman WP, Downing JR, Relling M, Yang J, Bhojwani D, Carroll WL, Camitta B, Reaman GH, Smith M, Hunger SP, Willman CL.

Blood. 2010 Dec 2;116(23):4874-84. doi: 10.1182/blood-2009-08-239681. Epub 2010 Aug 10.

38.

Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH.

J Clin Oncol. 2010 May 20;28(15):2625-34. doi: 10.1200/JCO.2009.27.0421. Epub 2010 Apr 19.

39.

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.

Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Reaman GH, Baker LH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Leukemia. 2010 May;24(5):909-13. doi: 10.1038/leu.2010.56. Epub 2010 Apr 8.

40.

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, Kang H, Liu W, Dobbin KK, Smith MA, Carroll WL, Devidas M, Bowman WP, Camitta BM, Reaman GH, Hunger SP, Downing JR, Willman CL.

Blood. 2010 Jul 1;115(26):5312-21. doi: 10.1182/blood-2009-09-245944. Epub 2010 Feb 4.

41.

Novel targeted drug therapies for the treatment of childhood acute leukemia.

Brown P, Hunger SP, Smith FO, Carroll WL, Reaman GH.

Expert Rev Hematol. 2009 Apr 1;2(9):145.

42.

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, Ar K, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, Camitta BM, Reaman GH, Smith MA, Downing JR, Hunger SP, Willman CL.

Blood. 2010 Feb 18;115(7):1394-405. doi: 10.1182/blood-2009-05-218560. Epub 2009 Oct 30.

43.

The ALARA concept in pediatric oncology.

Voss SD, Reaman GH, Kaste SC, Slovis TL.

Pediatr Radiol. 2009 Nov;39(11):1142-6. doi: 10.1007/s00247-009-1404-5. Epub 2009 Sep 30. No abstract available.

PMID:
19789861
44.

Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Children's Cancer Group Protocol 1953: a report from the Children's Oncology Group.

Salzer W, Dinndorf P, Dreyer Z, Hilden J, Reaman GH.

J Pediatr Hematol Oncol. 2009 Jun;31(6):398-405. doi: 10.1097/MPH.0b013e3181a6dec0.

PMID:
19648788
45.

JAK mutations in high-risk childhood acute lymphoblastic leukemia.

Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8. doi: 10.1073/pnas.0811761106. Epub 2009 May 22.

46.

Late effects in long-term survivors after treatment for childhood acute leukemia.

Haddy TB, Mosher RB, Reaman GH.

Clin Pediatr (Phila). 2009 Jul;48(6):601-8. doi: 10.1177/0009922809332680. Epub 2009 Mar 4.

PMID:
19264722
47.

What, why, and when we image: considerations for diagnostic imaging and clinical research in the Children's Oncology Group.

Reaman GH.

Pediatr Radiol. 2009 Feb;39 Suppl 1:S42-5. doi: 10.1007/s00247-008-1065-9. Epub 2008 Dec 16. Review.

48.

Prevention of hearing loss in children receiving cisplatin chemotherapy.

Freyer DR, Sung L, Reaman GH.

J Clin Oncol. 2009 Jan 10;27(2):317-8; author reply 318-9. doi: 10.1200/JCO.2008.20.1160. Epub 2008 Dec 8. No abstract available.

PMID:
19064953
49.

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.

Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM.

J Clin Oncol. 2009 Jan 1;27(1):85-91. doi: 10.1200/JCO.2006.10.3564. Epub 2008 Dec 1.

50.

Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group.

O'Leary M, Krailo M, Anderson JR, Reaman GH; Children's Oncology Group.

Semin Oncol. 2008 Oct;35(5):484-93. doi: 10.1053/j.seminoncol.2008.07.008. Review.

Supplemental Content

Loading ...
Support Center